Search results
Results from the WOW.Com Content Network
An orexigenic, or appetite stimulant, is a drug, hormone, or compound that increases appetite and may induce hyperphagia.This can be a medication or a naturally occurring neuropeptide hormone, such as ghrelin, orexin or neuropeptide Y, [1] [2] which increases hunger and therefore enhances food consumption.
Common side effects may include cataracts, bone loss, easy bruising, muscle weakness, and thrush. [3] Other side effects include weight gain, swelling, high blood sugar, increased risk of infection, and psychosis. [4] [3] It is generally considered safe in pregnancy and low doses appear to be safe while the user is breastfeeding. [5]
GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the average user. (Reminder that there are many of these meds now.
Excess adipose tissue can lead to medical problems; however, a round or large figure does not necessarily imply a medical problem, and is sometimes not primarily caused by adipose tissue. If too much weight is gained, serious health side-effects may follow. A large number of medical conditions have been associated with obesity.
However, many are associated with an infamous side effect: weight gain. Luckily, some antidepressants are less likely to cause weight gain than others. In fact, there are even some antidepressants ...
Weight gain. Some side effects, such as weight gain, occur more frequently with certain types of antidepressant medication. Switching to a new type of antidepressant may help reverse any weight ...
uBreakiFix is an American chain of electronic repair shops, founded in 2009 with over 832 locations in 2016 across the United States and the Caribbean. [1] [2] [3] They are most commonly known for repairing all kinds of household electronics. [4] In August 2019, uBreakiFix was acquired by Asurion, LLC, an insurance company. [5]
[1] [2] These side effects are serious and some of them are permanent, and many remain a crucial concern for companies and healthcare professionals and substantial efforts are being encouraged to reduce the potential risks for future antipsychotics through more clinical trials and drug development.